Preclinical Anticancer Activity of an Electron‐Deficient Organoruthenium(II) Complex

• Published in: ChemMedChem Vol. 15; no. 11; pp. 982 - 987
• Main Authors: Soldevila‐Barreda, Joan J., Azmanova, Maria, Pitto‐Barry, Anaïs, Cooper, Patricia A., Shnyder, Steven D., Barry, Nicolas P. E.
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 04.06.2020
• Subjects: Animals; Anticancer properties; Antineoplastic Agents - chemical synthesis; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Antitumor activity; Apoptosis - drug effects; Biotechnology; Cancer; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Cisplatin; Colon; Coordination Complexes - chemical synthesis; Coordination Complexes - chemistry; Coordination Complexes - pharmacology; Cymene; Cytotoxicity; Dose-Response Relationship, Drug; Drug development; Drug Screening Assays, Antitumor; electron-deficient; Electrons; half-sandwich complexes; hollow fibre assay; Humans; In vivo methods and tests; in vivo evaluation; Lung cancer; metallodrugs; Mice; Molecular Structure; Neoplasms, Experimental - drug therapy; Neoplasms, Experimental - metabolism; Neoplasms, Experimental - pathology; Non-small cell lung carcinoma; Organoruthenium complexes; p53 Protein; Platinum; Reactive Oxygen Species - metabolism; Ruthenium; Ruthenium - chemistry; Ruthenium - pharmacology; Ruthenium compounds; Structure-Activity Relationship; Tumor cell lines; Xenografts; Xenotransplantation; in vivo evaluation; half-sandwich complexes; metallodrugs; hollow fibre assay; electron-deficient

Ruthenium compounds have been shown to be promising alternatives to platinum(II) drugs. However, their clinical success depends on achieving mechanisms of action that overcome Pt‐resistance mechanisms. Electron‐deficient organoruthenium complexes are an understudied class of compounds that exhibit u...